<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: We examined the cytoprotective effect of the <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation inhibitor tirilazad mesylate (U74006F) in <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e> of neocortical infarction induced by transient and permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Wistar rats (experiment 1) and spontaneously hypertensive rats (experiment 2) were subjected to 2 hours of transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> followed by 22 hours of reperfusion and pretreated with 10 mg/kg i.p. tirilazad, vehicle, or saline </plain></SENT>
<SENT sid="2" pm="."><plain>Repeat doses were given at 4 and 10 hours after reperfusion </plain></SENT>
<SENT sid="3" pm="."><plain>Spontaneously hypertensive rats were also subjected to permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and either pretreated with tirilazad, vehicle, or saline intraperitoneally (experiment 3) or treated with either tirilazad or vehicle intravenously after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (experiment 4) </plain></SENT>
<SENT sid="4" pm="."><plain>Cortical <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes were measured 24 hours after the <z:hpo ids='HP_0003674'>onset</z:hpo> of either transient or permanent <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, and changes in core regional cerebral blood flow were monitored with laser Doppler flowmetry </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Tirilazad reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume after <z:e sem="disease" ids="C0022118" disease_type="Disease or Syndrome" abbrv="">transient ischemia</z:e> by 40% in Wistar rats (p = 0.08) (experiment 1) and 23% in spontaneously hypertensive rats (p less than 0.05) (experiment 2) but did not reduce infarction after permanent <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> whether it was given intraperitoneally (experiment 3) or intravenously (experiment 4) </plain></SENT>
<SENT sid="6" pm="."><plain>Ischemic core blood flows were not affected during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, nor were they affected during reperfusion after <z:e sem="disease" ids="C0022118" disease_type="Disease or Syndrome" abbrv="">transient ischemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Tirilazad reduces cortical infarction in transient but not permanent <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, an effect not related to improvement in regional cerebral blood flow </plain></SENT>
<SENT sid="8" pm="."><plain>Tirilazad might prove to be useful as an adjuvant therapy after successful thrombolysis in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> patients </plain></SENT>
</text></document>